Stock IBRX IMMUNITYBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq
Other stock markets
 03:59:47 2024-06-04 pm EDT 		5-day change 1st Jan Change
6.155 USD -0.73% Intraday chart for ImmunityBio, Inc. -7.02% +22.61%
May. 09 ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment MT

Evolution of the average Target Price on ImmunityBio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

db83b81082ee8360b3.cWHVKuOfbrTdKkRPGNylLfnpbb5KKAK6YWSnoV5_VOM.HBS3ZoHSI_6xEyt5KInGWpeqP40LGW3_LyPzzikpIJAJJexTj8wt0uR4Iw~0bcaabe6860080a4c1398ff9750934e3

Analyst Recommendations on ImmunityBio, Inc.

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance MT
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating MT
Piper Sandler Downgrades ImmunityBio to Neutral From Overweight, Cuts Price Target to $4 From $10 MT
Jefferies Starts ImmunityBio at Buy With $8 Price Target MT
Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating MT
ImmunityBio : Says Phase 2/3 Trial in BCG-Unresponsive Bladder Cancer Patients Achieves Complete Response Rate of 72% MT
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial CI
Nantkwest : Reports Positive Interim Data on Survival Rates from Pivotal Pancreatic Cancer Trials; Shares Hit New 52-Week High MT
NantKwest, Inc. and ImmunityBio, Inc. Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials CI
ImmunityBio, Inc. Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.15 USD
Average target price
7.5 USD
Spread / Average Target
+21.95%
High Price Target
9 USD
Spread / Highest target
+46.34%
Low Price Target
6 USD
Spread / Lowest Target
-2.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ImmunityBio, Inc.

Piper Sandler
Jefferies & Co.

Ratings for ImmunityBio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. Consensus ImmunityBio, Inc.